ArticleEuropean journal of gynaecological oncology2023

Timing and duration of bevacizumab treatment and survival in patients with recurrent ovarian, fallopian tube, and peritoneal cancer: a multi-institution study.

Talayeh S Ghezelayagh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.